-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HIV-1-protease-IN-7
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/hiv-1-protease-in-7.gif)
| Category | HIV Integrase |
| Description | HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM). |
Product Information
| Molecular Weight | 1285.68 |
| Molecular Formula | C68H104N10O12S |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | HIV-1 protease-IN-7 (2.57 mg/kg; p.o.; single) exhibits good plasma total clearance and oral bioavailability. |
| Target | IC50: 0.021 nM (HIV-1 protease) EC50: 0.74 μM (HIV-1 NL4-3), 0.61 μM (HIV DRVRs) |
